Methods of producing anti-C5 antibodies
US12312394B2 · kind B2 · utility
0Cited by
57References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 27, 2019 |
| Grant date | May 27, 2025 |
| Priority date | — |
| Expiry date | Jun 18, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldChemical engineering
- WIPO sectorChemistry
Abstract
The present application relates to a method of producing an anti-C5 antibody (ravulizumab), wherein the method comprises: —culturing mammalian cells comprising a nucleic acid encoding the anti-C5 antibody in a cell culture production medium—Performing two or more steps selected from the group consisting of: a recovery step; purification by Protein A affinity chromatography, a low pH viral inactivation step; Purification by cation exchange chromatography; Purification by anion exchange chromatography; a virus reduction filtration step; and a concentration and diafiltration step.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.